Active clinical trials

Clinical Trials - Diseases by specialty group


Solid Tumors 19


    A Phase 1/2 Study of Nivolumab (Ind# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

    COG-ADVL1414
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

    COG-ADVL1921
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Other Solid Tumor
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors

    Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

    COG-APEC1621A
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Other Solid Tumor
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions

    COG-APEC1621B
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Other Solid Tumor
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations

    COG-APEC1621D
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Other Solid Tumor
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    NCI-COG PEDIATRIC MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors

    COG-APEC1621F
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Other Solid Tumor
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations

    COG-APEC1621H
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Other Solid Tumor
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes

    COG-APEC1621SC
  • Ewing Sarcoma
  • Germ Cell Tumors
  • Hepatoblastoma
  • Neuroblastoma
  • Osteosarcoma
  • Other Solid Tumor
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms Tumor/Nephroblastoma
    NCI - COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

    SPOC-2012-001
  • Ewing Sarcoma
  • Neuroblastoma
  • Osteosarcoma
  • Rhabdomyosarcoma
    Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

    A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

    Pediatric Hepatic Malignancy International Therapeutic Trial

    Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study

    A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

    Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy

    Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

    A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma

    A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

For more information about cancer and blood disorders clinical trials, email us or call

(414) 955-4727

It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.

Michael Burke, MD

"The steady improvement in survival for children with cancer is a direct result of their enrollment onto clinical trials; without which we would remain decades behind in terms of scientific advances in pediatric cancer." ~Michael J. Burke, MD